[{"id":"c70f6861-a666-4861-ad3d-2301e394ab62","acronym":"ASCEND","url":"https://clinicaltrials.gov/study/NCT02970318","created_at":"2021-01-17T17:36:01.594Z","updated_at":"2025-02-25T14:01:11.516Z","phase":"Phase 3","brief_title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","source_id_and_acronym":"NCT02970318 - ASCEND","lead_sponsor":"Acerta Pharma BV","biomarkers":" CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib) • Zydelig (idelalisib) • bendamustine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 310","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-19"},{"id":"ed362182-add1-434a-b6df-44f932cad804","acronym":"","url":"https://clinicaltrials.gov/study/NCT02135133","created_at":"2021-01-18T09:54:33.334Z","updated_at":"2025-02-25T13:11:11.926Z","phase":"Phase 2","brief_title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","source_id_and_acronym":"NCT02135133","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zydelig (idelalisib) • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-10-16"},{"id":"e11fa619-feab-4b71-950e-0952bd0a0f35","acronym":"","url":"https://clinicaltrials.gov/study/NCT02332980","created_at":"2021-01-18T11:04:34.890Z","updated_at":"2024-07-02T16:35:24.706Z","phase":"Phase 2","brief_title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT02332980","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • PD-1 • CCND1 • IGH • PD-L2 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imbruvica (ibrutinib) • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 02/19/2015","start_date":" 02/19/2015","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 01/04/2022","study_completion_date":" 01/04/2022","last_update_posted":"2024-01-03"},{"id":"63428840-a847-4c4e-95af-72ccd46e2e94","acronym":"GIMEMA-ERIC","url":"https://clinicaltrials.gov/study/NCT03545035","created_at":"2021-01-18T17:27:17.189Z","updated_at":"2024-07-02T16:36:10.548Z","phase":"","brief_title":"Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study","source_id_and_acronym":"NCT03545035 - GIMEMA-ERIC","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 104","initiation":"Initiation: 02/06/2019","start_date":" 02/06/2019","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 10/28/2020","study_completion_date":" 10/28/2020","last_update_posted":"2022-05-12"},{"id":"454d62f2-5ae5-42d9-b53f-9ec7a363eaa8","acronym":"RIVe-CLL/SLL","url":"https://clinicaltrials.gov/study/NCT03639324","created_at":"2021-01-18T17:52:09.658Z","updated_at":"2024-07-02T16:36:20.922Z","phase":"Phase 1","brief_title":"Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL","source_id_and_acronym":"NCT03639324 - RIVe-CLL/SLL","lead_sponsor":"Virginia Commonwealth University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Zydelig (idelalisib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/02/2020","start_date":" 10/02/2020","primary_txt":" Primary completion: 10/18/2021","primary_completion_date":" 10/18/2021","study_txt":" Completion: 10/18/2021","study_completion_date":" 10/18/2021","last_update_posted":"2021-11-09"},{"id":"1de0ad14-ef75-4a77-8076-2b0d47bc5454","acronym":"","url":"https://clinicaltrials.gov/study/NCT01644799","created_at":"2021-01-18T07:05:04.632Z","updated_at":"2025-02-25T14:33:34.003Z","phase":"Phase 1","brief_title":"Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma","source_id_and_acronym":"NCT01644799","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2018-01-30"},{"id":"dc19de0c-28d4-42a3-955e-a4ce4a7a4f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01838434","created_at":"2021-01-18T08:11:13.057Z","updated_at":"2025-02-25T14:34:08.679Z","phase":"Phase 2","brief_title":"Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT01838434","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CCND1 • CD4 • CD5 • FCER2","pipe":" | ","alterations":" CCND1 expression","tags":["CCND1 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Zydelig (idelalisib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 09/30/2014","primary_completion_date":" 09/30/2014","study_txt":" Completion: 05/01/2017","study_completion_date":" 05/01/2017","last_update_posted":"2018-01-30"}]